Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Dec;24(6):781–791. doi: 10.1111/j.1365-2125.1987.tb03246.x

Disopyramide pharmacokinetics and metabolism: effect of inducers.

R P Kapil 1, J E Axelson 1, I L Mansfield 1, D J Edwards 1, B McErlane 1, M A Mason 1, D Lalka 1, C R Kerr 1
PMCID: PMC1386404  PMID: 3440098

Abstract

1. The disposition of orally administered disopyramide was studied in a population of smokers (n = 6) and non-smokers (n = 8) before and during phenobarbitone treatment (100 mg daily for 21 days; Cp 21st day = 13.9 +/- 2.0 micrograms ml-1). The comparative inducibility of these populations by phenobarbitone was assessed as was the inductive effect of cigarette smoking, per se. Furthermore, the determinants of the intensity of the inductive effect were examined, as well as the effect of the barbiturate on the binding of disopyramide to alpha 1-acid glycoprotein (AGP). 2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment. 3. Both populations responded comparably to barbiturate exposure in that apparent intrinsic metabolic clearance more than doubled. Interestingly, the magnitude of this increase was highly dependent on the observed baseline apparent intrinsic metabolic clearance, (r' = 0.81; P less than 0.001). 4. Phenobarbitone treatment of non-smokers resulted in an increase in the AUC of the active metabolite N-despropyl disopyramide (MND), but not significantly (3.8 +/- 1.6 vs 4.1 +/- 2.3 micrograms ml-1 h). Similar results were observed in smokers (3.5 +/- 1.4 vs 3.9 +/- 2.0 micrograms ml-1 h, respectively). 5. The percent of administered dose recovered in urine as disopyramide in non-smokers was significantly decreased upon phenobarbitone treatment (43 +/- 6% vs 25 +/- 5%), whereas the percent of dose recovered as MND increased significantly in this group (25 +/- 6% vs 31 +/- 5%). The population of smokers responded similarly. 6. At doses typically used to achieve hepatic microsomal enzyme induction in man, phenobarbitone treatment caused no significant change or trend towards a change in serum AGP concentrations as measured using the radial immunodiffusion method in nonsmokers (67.4 +/- 19.9 mg dl-1 vs 68.0 +/- 40.7 mg dl-1) or smokers (64.5 +/- 15.7 vs 67.9 +/- 14.9). Similarly, when AGP concentration was estimated in serum from non-smokers using a nephelometric method no effect attributable to phenobarbitone was observed (47.9 +/- 1.3 vs 47.9 +/- 16.8 mg dl-1). Consistent with this observation, disopyramide free fraction was not affected by barbiturate treatment.

Full text

PDF
781

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alván G., Piafsky K., Lind M., von Bahr C. Effect of pentobarbital on the disposition of alprenolol. Clin Pharmacol Ther. 1977 Sep;22(3):316–321. doi: 10.1002/cpt1977223316. [DOI] [PubMed] [Google Scholar]
  2. Bai S. A., Abramson F. P. Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. J Pharmacol Exp Ther. 1982 Sep;222(3):589–594. [PubMed] [Google Scholar]
  3. Beckett A. H., Triggs E. J. Enzyme induction in man caused by smoking. Nature. 1967 Nov 11;216(5115):587–587. doi: 10.1038/216587a0. [DOI] [PubMed] [Google Scholar]
  4. Benedek I. H., Fiske W. D., 3rd, Griffen W. O., Bell R. M., Blouin R. A., McNamara P. J. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol. 1983 Dec;16(6):751–754. doi: 10.1111/j.1365-2125.1983.tb02258.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bonde J., Pedersen L. E., Bødtker S., Angelo H. R., Svendsen T. L., Kampmann J. P. The influence of age and smoking on the elimination of disopyramide. Br J Clin Pharmacol. 1985 Nov;20(5):453–458. doi: 10.1111/j.1365-2125.1985.tb05096.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brinkschulte M., Breyer-Pfaff U. Increased binding of desmethylimipramine in plasma of phenobarbital-treated rats. Biochem Pharmacol. 1982 May 1;31(9):1749–1754. doi: 10.1016/0006-2952(82)90679-7. [DOI] [PubMed] [Google Scholar]
  7. Bruguerolle B., Jadot G., Bussiere H. Together, phenobarbital and carbamazepine lower the alpha 1-acid glycoprotein concentration in plasma of epileptic patients. Clin Chem. 1984 Apr;30(4):590–591. [PubMed] [Google Scholar]
  8. Huang J. D., Oie S. Effect of altered disopyramide binding on its pharmacologic response in rabbits. J Pharmacol Exp Ther. 1982 Nov;223(2):469–471. [PubMed] [Google Scholar]
  9. Hunt S. N., Jusko W. J., Yurchak A. M. Effect of smoking on theophylline disposition. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):546–551. doi: 10.1002/cpt1976195part1546. [DOI] [PubMed] [Google Scholar]
  10. Kapil R. P., Abbott F. S., Kerr C. R., Edwards D. J., Lalka D., Axelson J. E. Simultaneous quantitation of disopyramide and its mono-dealkylated metabolite in human plasma by fused-silica capillary gas chromatography using nitrogen-phosphorus specific detection. J Chromatogr. 1984 May 11;307(2):305–321. doi: 10.1016/s0378-4347(00)84102-x. [DOI] [PubMed] [Google Scholar]
  11. Kapil R. P., Axelson J. E., Lalka D., Edwards D. J., Kerr C. R. Applicability of capillary gas liquid chromatography to the measurement of free fraction of disopyramide in human plasma. Res Commun Chem Pathol Pharmacol. 1985 Apr;48(1):153–156. [PubMed] [Google Scholar]
  12. Meffin P. J., Robert E. W., Winkle R. A., Harapat S., Peters F. A., Harrison D. C. Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm. 1979 Feb;7(1):29–46. doi: 10.1007/BF01059439. [DOI] [PubMed] [Google Scholar]
  13. Niarchos A. P. Disopyramide: serum level and arrhythmia conversion. Am Heart J. 1976 Jul;92(1):57–64. doi: 10.1016/s0002-8703(76)80403-6. [DOI] [PubMed] [Google Scholar]
  14. Pape B. E. Enzyme immunoassay of disopyramide in serum. Clin Chem. 1981 Dec;27(12):2038–2040. [PubMed] [Google Scholar]
  15. Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet. 1982 Jan-Feb;7(1):57–84. doi: 10.2165/00003088-198207010-00004. [DOI] [PubMed] [Google Scholar]
  16. Rane A., Wilkinson G. R., Shand D. G. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther. 1977 Feb;200(2):420–424. [PubMed] [Google Scholar]
  17. Routledge P. A., Stargel W. W., Finn A. L., Barchowsky A., Shand D. G. Lignocaine disposition in blood in epilepsy. Br J Clin Pharmacol. 1981 Nov;12(5):663–666. doi: 10.1111/j.1365-2125.1981.tb01286.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Thibonnier M., Holford N. H., Upton R. A., Blume C. D., Williams R. L. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. J Pharmacokinet Biopharm. 1984 Dec;12(6):559–573. doi: 10.1007/BF01059552. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES